膀胱肿瘤经尿道电切术中组织病理学评估对根治性膀胱切除术候选患者生存的影响
基于九中心2000–2023年3160例膀胱癌患者数据,评估经尿道膀胱肿瘤电切术(TURBT)与根治性膀胱切除术(RC)组织学诊断不一致对癌症特异性死亡率(CSM)的影响,发现21.6%患者诊断不一致,不一致诊断与更高CSM相关(HR 1.3,95%CI 1.1–1.6;P=0.002)。
要点
- TURBT与RC组织学诊断不一致者占21.6%,非尿路上皮癌亚型一致性仅为一般(Cohen kappa 0.32)。
- 诊断不一致与更高CSM相关(HR 1.3,95%CI 1.1–1.6;P=0.002)。
- 在未接受新辅助化疗的尿路上皮癌患者中,不一致的生存劣势更明显(HR 1.5,95%CI 1.1–1.7;P=0.04)。
核心结论
- TURBT与RC组织病理学诊断不一致与更高CSM率相关,尤其在初诊为尿路上皮癌的病例中。
- TURBT与RC在识别非尿路上皮癌亚型方面一致性为中等(原文表述为fair concordance,Cohen kappa 0.32)。
研究设计与样本
- 多机构数据库研究,纳入九个中心2000年至2023年间接受TURBT及后续RC的膀胱癌患者,共3160例。
- 以RC为参考标准,采用Cohen kappa系数评估TURBT与RC检测尿路上皮癌及非尿路上皮癌组织学亚型的一致性。
- 生存分析采用Kaplan-Meier曲线和多变量Cox回归模型,按TURBT与RC诊断一致(一致 vs 不一致)评估CSM。
主要发现
- TURBT时2762例(87%)为尿路上皮癌、398例(13%)为非尿路上皮癌;RC时2481例(79%)为尿路上皮癌、679例(21%)为非尿路上皮癌。
- 683例(21.6%)患者TURBT与RC诊断不一致。
- 检测非尿路上皮癌亚型的总体一致性为fair concordance(Cohen kappa系数0.32)。
- 多变量Cox回归中,诊断不一致者较诊断一致者CSM更高(HR 1.3,95%CI 1.1–1.6;P=0.002)。
- 敏感性分析纳入未接受新辅助化疗的尿路上皮癌患者,该生存劣势更大(HR 1.5,95%CI 1.1–1.7;P=0.04)。
关键数值与推荐
- 诊断不一致定义为TURBT与RC识别的特定组织学亚型不一致,一致性以Cohen kappa系数评估。
- 非尿路上皮癌亚型检测一致性为fair concordance(Cohen kappa系数0.32)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of discordant histological diagnoses between transurethral resection of bladder tumour (TURBT) and radical cystectomy (RC) on cancer-specific mortality (CSM) in patients with bladder cancer (BCa). PATIENTS AND METHODS: We relied on a multi-institutional database collecting data of patients with BCa who underwent TURBT and subsequent RC from nine centres between 2000 and 2023. We tested concordance rates between TURBT and RC in detecting urothelial carcinoma of the urinary bladder (UCUB) as well as non-UCUB hystological subtypes, using RC as the reference standard. Concordance was defined as the agreement between a specific histological subtype identified both at TURBT and RC and evaluated according to Cohen's kappa coefficient. Subsequently, survival analyses consisted of Kaplan-Meier plots and multivariable Cox regression (MCR) models addressing CSM according to concordance between TURBT and RC (namely, concordant vs discordant). RESULTS: Overall, 3160 patients were identified. Of these, 2762 (87%) harboured UCUB and 398 (13%) non-UCUB at TURBT vs 2481 (79%) UCUB and 679 (21%) non-UCUB at RC. There were 683 (21.6%) patients with a discordant diagnosis between TURBT and RC. The overall concordance in detecting non-UCUB subtypes was defined as fair concordance (Cohen's kappa coefficient: 0.32). In MCR models, a discordant diagnosis exhibited higher CSM relative to those with a concordant diagnosis (hazard ratio [HR] 1.3, 95% confidence interval [CI] 1.1-1.6; P = 0.002). In a sensitivity analysis including patients with UCUB not exposed to neoadjuvant chemotherapy, this survival disadvantage was even higher (HR 1.5, 95% CI 1.1-1.7; P = 0.04). CONCLUSIONS: A discordant histopathological diagnosis between TURBT and RC is associated with higher CSM rates, particularly in cases initially misdiagnosed as UCUB. However, we also observed a moderate concordance between TURBT and RC in identifying non-UCUB subtypes.
引用
- de Angelis M, Scilipoti P, Santangelo A, et al. The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidates. BJU Int. 2025. PMID: 40135788. doi:10.1111/bju.16714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。